Total Skin Electron Beam Therapy as Part of Multimodal Treatment Strategies for Primary Cutaneous T-Cell Lymphoma

Oncology Research and Treatment

Volumn 40, Issue 5, 2017, Pages 244-252

  Elsayad, Khaled ^a   Susek, Katharina H ^a   Eich, Hans T ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

Immunotherapy; Mycosis fungoides; Radiotherapy; Skin directed; Systemic therapy; S zary syndrome; Total skin electron beam therapy

Indexed keywords

ALEMTUZUMAB; BELINOSTAT; BEXAROTENE; BORTEZOMIB; BRENTUXIMAB VEDOTIN; CHLORMETHINE; DENILEUKIN DIFTITOX; ENTINOSTAT; FORODESINE; LENALIDOMIDE; METHOTREXATE; MOGAMULIZUMAB; PANOBINOSTAT; PRALATREXATE; QUISINOSTAT; ROMIDEPSIN; VORINOSTAT; ZANOLIMUMAB;

ALOPECIA; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER STAGING; CLINICAL EFFECTIVENESS; CUTANEOUS T CELL LYMPHOMA; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG TOLERABILITY; EYE IRRITATION; FATIGUE; HUMAN; LEG EDEMA; LONG TERM SURVIVAL; MAINTENANCE THERAPY; MYCOSIS FUNGOIDES; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; RADIATION DOSE; RADIATION SAFETY; RECURRENCE FREE SURVIVAL; REVIEW; SEZARY SYNDROME; SKIN MANIFESTATION; SURVIVAL TIME; TOTAL SKIN ELECTRON THERAPY; TREATMENT RESPONSE; ULTRAVIOLET B RADIATION; XEROSIS; ELECTRON; EVIDENCE BASED MEDICINE; FEMALE; MALE; MEGAVOLTAGE RADIOTHERAPY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROCEDURES; RADIATION INJURY; RADIATION RESPONSE; RADIOTHERAPY DOSAGE; SKIN TUMOR; THERAPEUTIC USE; TREATMENT OUTCOME;

COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, RADIATION; ELECTRONS; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; LYMPHOMA, T-CELL, CUTANEOUS; MALE; RADIATION INJURIES; RADIOTHERAPY DOSAGE; RADIOTHERAPY, HIGH-ENERGY; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 85018305967     PISSN: 22965270     EISSN: 22965262     Source Type: Journal    
DOI: 10.1159/000475634     Document Type: Review

References (79)

1. Bradford PT, Devesa SS, Anderson WF, Toro JR: Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3, 884 cases. Blood 2009; 113: 5064-5073.
2. Bagherani N, Smoller BR: An overview of cutaneous T cell lymphomas. F1000Res 2016; 5.
3. Willemze R, Jaffe ES, Burg G, Cerroni L, Berti E, Swerdlow SH, Ralfkiaer E, Chimenti S, Diaz-Perez JL, Duncan LM, Grange F, Harris NL, Kempf W, Kerl H, Kurrer M, Knobler R, Pimpinelli N, Sander C, Santucci M, Sterry W, Vermeer MH, Wechsler J, Whittaker S, Meijer CJ: WHO-EORTC classification for cutaneous lymphomas. Blood 2005; 105: 3768-3785.
4. Olsen E, Vonderheid E, Pimpinelli N, Willemze R, Kim Y, Knobler R, Zackheim H, Duvic M, Estrach T, Lamberg S, Wood G, Dummer R, Ranki A, Burg G, Heald P, Pittelkow M, Bernengo M-G, Sterry W, Laroche L, Trautinger F, Whittaker S: Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 2007; 110: 1713-1722.
5. Agar NS, Wedgeworth E, Crichton S, Mitchell TJ, Cox M, Ferreira S, Robson A, Calonje E, Stefanato CM, Wain EM, Wilkins B, Fields PA, Dean A, Webb K, Scarisbrick J, Morris S, Whittaker SJ: Survival outcomes and prognostic factors in mycosis fungoides/ Sezary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal. J Clin Oncol 2010; 28: 4730-4739.
6. Kim YH, Willemze R, Pimpinelli N, Whittaker S, Olsen EA, Ranki A, Dummer R, Hoppe RT: TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 2007; 110: 479-484.
7. Jones GW, Kacinski BM, Wilson LD, Willemze R, Spittle M, Hohenberg G, Handl-Zeller L, Trautinger F, Knobler R: Total skin electron radiation in the management of mycosis fungoides: consensus of the European Organization for Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Project Group. J Am Acad Dermatol 2002; 47: 364-370.
8. Harrison C, Young J, Navi D, Riaz N, Lingala B, Kim Y, Hoppe R: Revisiting low-dose total skin electron beam therapy in mycosis fungoides. Int J Radiat Oncol Biol Phys 2011; 81:e651-e657.
9. Elsayad K, Kriz J, Moustakis C, Scobioala S, Reinartz G, Haverkamp U, Willich N, Weishaupt C, Stadler R, Sunderkotter C, Eich HT: Total skin electron beam for primary cutaneous T-cell lymphoma. Int J Radiat Oncol Biol Phys 2015; 93: 1077-1086.
10. Heumann TR, Esiashvili N, Parker S, Switchenko JM, Dhabbaan A, Goodman M, Lechowicz MJ, Flowers CR, Khan MK: Total skin electron therapy for cutaneous T-cell lymphoma using a modern dual-field rotational technique. Int J Radiat Oncol Biol Phys 2015; 92: 183-191.
11. Willemze R, Hodak E, Zinzani PL, Specht L, Ladetto M: Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow- up. Ann Oncol 2013; 24(suppl 6):vi149-154.
12. Horwitz SM, Zelenetz AD, Gordon LI, Wierda WG, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Byrd JC, Fayad LE, Fisher RI, Glenn MJ, Habermann TM, Harris NL, Hernandez-Ilizaliturri F, Hoppe RT, Kaminski MS, Kelsey CR, Kim YH, Krivacic S, La Casce AS, Lunning M, Nademanee A, Press O, Rabinovitch R, Reddy N, Reid E, Roberts K, Saad AA, Sokol L, Swinnen LJ, Vose JM, Yahalom J, Zafar N, Dwyer M, Sundar H, Porcu P: NCCN guidelines insights: nonhodgkin's lymphomas, version 3.2016. J Natl Compr Canc Netw 2016; 14: 1067-1079.
13. Specht L, Dabaja B, Illidge T, Wilson LD, Hoppe RT: Modern radiation therapy for primary cutaneous lymphomas: field and dose guidelines from the International Lymphoma Radiation Oncology Group. Int J Radiat Oncol Biol Phys 2015; 92: 32-39.
14. Trautinger F, Eder J, Assaf C, Bagot M, Cozzio A, Dummer R, Gniadecki R, Klemke C-D, Ortiz-Romero PL, Papadavid E, Pimpinelli N, Quaglino P, Ranki A, Scarisbrick J, Stadler R, Vakeva L, Vermeer MH, Whittaker S, Willemze R, Knobler R: European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/ Sezary syndrome - Update 2017. Eur J Cancer 2017; 77: 57-74.
15. Horwitz SM, Olsen EA, Duvic M, Porcu P, Kim YH: Review of the treatment of mycosis fungoides and Sézary syndrome: a stage-based approach. J Natl Compr Canc Netw 2008; 6: 436-442.
16. Whittaker S, Hoppe R, Prince HM: How I treat mycosis fungoides and Sezary syndrome. Blood 2016; 127: 3142-3153.
17. Hoppe RT, Wood GS, Abel EA: Mycosis fungoides and the Sézary syndrome: pathology, staging, and treatment. Curr Probl Cancer 1990; 14: 297-361.
18. Jain S, Zain J, O'Connor O: Novel therapeutic agents for cutaneous T-cell lymphoma. J Hematol Oncol 2012; 5: 24.
19. Kim YH, Gratzinger D, Harrison C, Brody JD, Czerwinski DK, Ai WZ, Morales A, Abdulla F, Xing L, Navi D, Tibshirani RJ, Advani RH, Lingala B, Shah S, Hoppe RT, Levy R: In situ vaccination against mycosis fungoides by intratumoral injection of a TLR9 agonist combined with radiation: a phase 1/2 study. Blood 2012; 119: 355-363.
20. Polansky M, Talpur R, Daulat S, Hosing C, Dabaja B, Duvic M: Long-term complete responses to combination therapies and allogeneic stem cell transplants in patients with Sezary syndrome. Clin Lymphoma Myeloma Leuk 2015; 15:e83-93.
21. Hosing C, Bassett R, Dabaja B, Talpur R, Alousi A, Ciurea S, Popat U, Qazilbash M, Shpall EJ, Oki Y, Nieto Y, Pinnix C, Fanale M, Maadani F, Donato M, Champlin R, Duvic M: Allogeneic stem-cell transplantation in patients with cutaneous lymphoma: updated results from a single institution. Ann Oncol 2015; 26: 2490-2495.
22. Scholtz W: Ueber den Einfluss der Röntgenstrahlen auf die Haut in gesundem und krankem Zustande. Archiv für Dermatologie und Syphilis 1902; 59: 421-446.
23. Trump JG, Wright KA, Evans WW, Anson JH, Hare HF, Fromer JL, Jacque G, Horne KW: High energy electrons for the treatment of extensive superficial malignant lesions. Am J Roentgenol Radium Ther Nucl Med 1953; 69: 623-629.
24. Karzmark CJ, Loevinger R, Steele RE, Weissbluth M: A technique for large-field, superficial electron therapy. Radiology 1960; 74: 633-644.
25. Lo TC, Salzman FA, Moschella SL, Tolman EL, Wright KA: Whole body surface electron irradiation in the treatment of mycosis fungoides. An evaluation of 200 patients. Radiology 1979; 130: 453-457.
26. Braverman IM, Yager NB, Chen M, Cadman EC, Hait WN, Maynard T: Combined total body electron beam irradiation and chemotherapy for mycosis fungoides. J Am Acad Dermatol 1987; 16: 45-60.
27. Dabaja B: Renaissance of low-dose radiotherapy concepts for cutaneous lymphomas. Oncol Res Treat 2017; 40.
28. Hoppe RT, Fuks Z, Bagshaw MA: Radiation therapy in the management of cutaneous T-cell lymphomas. Cancer Treat Rep 1979; 63: 625-632.
29. Kamstrup MR, Gniadecki R, Iversen L, Skov L, Petersen PM, Loft A, Specht L: Low-dose (10-Gy) total skin electron beam therapy for cutaneous T-cell lymphoma: an open clinical study and pooled data analysis. Int J Radiat Oncol Biol Phys 2015; 92: 138-143.
30. Hoppe RT, Harrison C, Tavallaee M, Bashey S, Sundram U, Li S, Million L, Dabaja B, Gangar P, Duvic M, Kim YH: Low-dose total skin electron beam therapy as an effective modality to reduce disease burden in patients with mycosis fungoides: results of a pooled analysis from 3 phase-II clinical trials. J Am Acad Dermatol 2015; 72: 286-292.
31. Elsayad K, Oertel M, Haverkamp U, Eich HT: The effectiveness of radiotherapy for leukemia cutis. J Cancer Res Clin Oncol 2017; 143: 851-859.
32. Diederen PVMM, van Weelden H, Sanders CJG, Toonstra J, van Vloten WA: Narrowband UVB and psoralen-UVA in the treatment of early-stage mycosis fungoides: a retrospective study. J Am Acad Dermatol 2003; 48: 215-219.
33. Thomsen K, Hammar H, Molin L, Volden G: Retinoids plus PUVA (RePUVA) and PUVA in mycosis fungoides, plaque stage. A report from the Scandinavian Mycosis Fungoides Group. Acta Derm Venereol 1989; 69: 536-538.
34. Roenigk HH, JR, Kuzel TM, Skoutelis AP, Springer E, Yu G, Caro W, Gilyon K, Variakojis D, Kaul K, Bunn PA, JR: Photochemotherapy alone or combined with interferon alpha-2a in the treatment of cutaneous Tcell lymphoma. J Invest Dermatol 1990; 95: 198S-205S.
35. Zackheim HS, Kashani-Sabet M, Amin S: Topical corticosteroids for mycosis fungoides. Experience in 79 patients. Arch Dermatol 1998; 134: 949-954.
36. Zic JA: The treatment of cutaneous T-cell lymphoma with photopheresis. Dermatol Ther 2003; 16: 337-346.
37. Panchal MR, Scarisbrick JJ: The utility of bexarotene in mycosis fungoides and Sezary syndrome. Onco Targets Ther 2015; 8: 367-373.
38. Duvic M, Lemak NA, Redman JR, Eifel PJ, Tucker SL, Cabanillas FF, Kurzrock R: Combined modality therapy for cutaneous T-cell lymphoma. J Am Acad Dermatol 1996; 34: 1022-1029.
39. Duvic M, Sherman ML, Wood GS, Kuzel TM, Olsen E, Foss F, Laliberte RJ, Ryan JL, Zonno K, Rook AH: A phase II open-label study of recombinant human interleukin-12 in patients with stage IA, IB, or IIA mycosis fungoides. J Am Acad Dermatol 2006; 55: 807-813.
40. Page V, Gardner A, Karzmark CJ: Patient dosimetry in the electron treatment of large superficial lesions. Radiology 1970; 94: 635-641.
41. Kumar PP, Henschke UK, Nibhanupudy JR: Problems and solutions in achieving uniform dose distribution in superficial total body electron therapy. J Natl Med Assoc 1977; 69: 645-647.
42. Quirós PA, Jones GW, Kacinski BM, Braverman IM, Heald PW, Edelson RL, Wilson LD: Total skin electron beam therapy followed by adjuvant psoralen/ultraviolet- A light in the management of patients with T1 and T2 cutaneous T-cell lymphoma (mycosis fungoides). Int J Radiat Oncol Biol Phys 1997; 38: 1027-1035.
43. Kim YH, Jensen RA, Watanabe GL, Varghese A, Hoppe RT: Clinical stage IA (limited patch and plaque) mycosis fungoides. A long-term outcome analysis. Arch Dermatol 1996; 132: 1309-1313.
44. Navi D, Riaz N, Levin YS, Sullivan NC, Kim YH, Hoppe RT: The Stanford University experience with conventional-dose, total skin electron-beam therapy in the treatment of generalized patch or plaque (T2) and tumor (T3) mycosis fungoides. Arch Dermatol 2011; 147: 561-567.
45. Hamminga B, Noordijk EM, van Vloten WA: Treatment of mycosis fungoides: total-skin electron-beam irradiation vs topical mechlorethamine therapy. Arch Dermatol 1982; 118: 150-153.
46. Klein RS, Dunlop JD, Samimi SS, Morrissey KA, Evans KG, Gardner JM, Introcaso CE, Vittorio CC, Rook AH, Micaily B, Kim EJ: Improvement in peripheral blood disease burden in patients with Sezary syndrome and leukemic mycosis fungoides after total skin electron beam therapy. J Am Acad Dermatol 2013; 68: 972-977.
47. Chinn DM, Chow S, Kim YH, Hoppe RT: Total skin electron beam therapy with or without adjuvant topical nitrogen mustard or nitrogen mustard alone as initial treatment of T2 and T3 mycosis fungoides. Int J Radiat Oncol Biol Phys 1999; 43: 951-958.
48. Price NM, Hoppe RT, Constantine VS, Fuks ZY, Farber EM: The treatment of mycosis fungoides: adjuvant topical mechlorethamine after electron beam therapy. Cancer 1977; 40: 2851-2853.
49. Lindahl LM, Kamstrup MR, Petersen PM, Wiren J, Fenger-Gron M, Gniadecki R, Iversen L, Specht L: Total skin electron beam therapy for cutaneous T-cell lymphoma: a nationwide cohort study from Denmark. Acta Oncol 2011; 50: 1199-1205.
50. Roberge D, Muanza T, Blake G, Shustik C, Vuong T, Freeman CR: Does adjuvant alpha-interferon improve outcome when combined with total skin irradiation for mycosis fungoides? Br J Dermatol 2007; 156: 57-61.
51. Jones G, McLean J, Rosenthal D, Roberts J, Sauder DN: Combined treatment with oral etretinate and electron beam therapy in patients with cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome). J Am Acad Dermatol 1992; 26: 960-967.
52. Wilson LD, Licata AL, Braverman IM, Edelson RL, Heald PW, Feldman AM, Kacinski BM: Systemic chemotherapy and extracorporeal photochemotherapy for T3 and T4 cutaneous T-cell lymphoma patients who have achieved a complete response to total skin electron beam therapy. Int J Radiat Oncol Biol Phys 1995; 32: 987-995.
53. Van Vloten WA, de Vroome H, Noordijk EM: Total skin electron beam irradiation for cutaneous T-cell lymphoma (mycosis fungoides). Br J Dermatol 1985; 112: 697-702.
54. Kaye FJ, Bunn PA, JR, Steinberg SM, Stocker JL, Ihde DC, Fischmann AB, Glatstein EJ, Schechter GP, Phelps RM, Foss FM: A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. N Engl J Med 1989; 321: 1784-1790.
55. Hughes CFM, Khot A, McCormack C, Lade S, Westerman DA, Twigger R, Buelens O, Newland K, Tam C, Dickinson M, Ryan G, Ritchie D, Wood C, Prince HM: Lack of durable disease control with chemotherapy for mycosis fungoides and Sezary syndrome: a comparative study of systemic therapy. Blood 2015; 125: 71-81.
56. Hoppe RT, Fuks Z, Bagshaw MA: The rationale for curative radiotherapy in mycosis fungoides. Int J Radiat Oncol Biol Phys 1977; 2: 843-851.
57. Becker M, Hoppe RT, Knox SJ: Multiple courses of high-dose total skin electron beam therapy in the management of mycosis fungoides. Int J Radiat Oncol Biol Phys 1995; 32: 1445-1449.
58. Ysebaert L, Truc G, Dalac S, Lambert D, Petrella T, Barillot I, Naudy S, Horiot J-C, Maingon P: Ultimate results of radiation therapy for T1-T2 mycosis fungoides (including reirradiation). Int J Radiat Oncol Biol Phys 2004; 58: 1128-1134.
59. Morris SL, McGovern M, Bayne S, Wain M, Child F, Whittaker S: Results of a 5-week schedule of modern total skin electron beam radiation therapy. Int J Radiat Oncol Biol Phys 2013; 86: 936-941.
60. Van Doorn R, Scheffer E, Willemze R: Follicular mycosis fungoides, a distinct disease entity with or without associated follicular mucinosis. Arch Dermatol 2002; 138: 191-198.
61. Wilson LD, Jones GW, Kim D, Rosenthal D, Christensen IR, Edelson RL, Heald PW, Kacinski BM: Experience with total skin electron beam therapy in combination with extracorporeal photopheresis in the management of patients with erythrodermic (T4) mycosis fungoides. J Am Acad Dermatol 2000; 43: 54-60.
62. Jones GW, Rosenthal D, Wilson LD: Total skin electron radiation for patients with erythrodermic cutaneous T-cell lymphoma (mycosis fungoides and the Sézary syndrome). Cancer 1999; 85: 1985-1995.
63. Duvic M, Tetzlaff MT, Gangar P, Clos AL, Sui D, Talpur R: Results of a phase II trial of brentuximab vedotin for CD30+ cutaneous T-cell lymphoma and lymphomatoid papulosis. J Clin Oncol 2015; 33: 3759-3765.
64. Duvic M, Pinter-Brown LC, Foss FM, Sokol L, Jorgensen JL, Challagundla P, Dwyer KM, Zhang X, Kurman MR, Ballerini R, Liu L, Kim YH: Phase 1/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous Tcell lymphoma. Blood 2015; 125: 1883-1889.
65. Ogura M, Ishida T, Hatake K, Taniwaki M, Ando K, Tobinai K, Fujimoto K, Yamamoto K, Miyamoto T, Uike N, Tanimoto M, Tsukasaki K, Ishizawa K, Suzumiya J, Inagaki H, Tamura K, Akinaga S, Tomonaga M, Ueda R: Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma. J Clin Oncol 2014; 32: 1157-1163.
66. Kim YH, Duvic M, Obitz E, Gniadecki R, Iversen L, Osterborg A, Whittaker S, Illidge TM, Schwarz T, Kaufmann R, Cooper K, Knudsen KM, Lisby S, Baadsgaard O, Knox SJ: Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphoma. Blood 2007; 109: 4655-4662.
67. Kim YH, Whittaker S, Horwitz SM, et al.: Brentuximab vedotin demonstrates significantly superior clinical outcomes in patients with CD30-expressing cutaneous T cell lymphoma versus physician's choice (methotrexate or bexarotene): the phase 3 Alcanza study. 2016 ASH Annual Meeting;abstr 182.
68. Lesokhin AM, Ansell SM, Armand P, Scott EC, Halwani A, Gutierrez M, Millenson MM, Cohen AD, Schuster SJ, Lebovic D, Dhodapkar M, Avigan D, Chapuy B, Ligon AH, Freeman GJ, Rodig SJ, Cattry D, Zhu L, Grosso JF, Bradley Garelik MB, Shipp MA, Borrello I, Timmerman J: Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase Ib study. J Clin Oncol 2016; 34: 2698-2704.
69. Bagot M, Porcu P, Ram-Wolff C, Khodadoust M, Battistella M, Marie-Cardine A, Mathieu S, Vermeer MH, Whittaker S, Duvic M, Bensussan A, Paturel C, Bonnafous C, Thonnart N, Widemann A, Bonin C, Sicard H, Paiva C, Pilz K, Kim Y: First-in-human, multicenter phase I study of IPH4102, first-in-class humanized anti-KIR3DL2 monoclonal antibody, in relapsed/refractory cutaneous T-cell lymphomas: preliminary safety, exploratory and clinical activity results. Blood 2016; 128: 1826.
70. Kamstrup MR, Specht L, Skovgaard GL, Gniadecki R: A prospective, open-label study of low-dose total skin electron beam therapy in mycosis fungoides. Int J Radiat Oncol Biol Phys 2008; 71: 1204-1207.
71. Wilson LD, Kacinski BM, Jones GW: Local superficial radiotherapy in the management of minimal stage IA cutaneous T-cell lymphoma (mycosis fungoides). Int J Radiat Oncol Biol Phys 1998; 40: 109-115.
72. Whittaker S, Ortiz P, Dummer R, Ranki A, Hasan B, Meulemans B, Gellrich S, Knobler R, Stadler R, Karrasch M: Efficacy and safety of bexarotene combined with psoralen-ultraviolet A (PUVA) compared with PUVA treatment alone in stage IB-IIA mycosis fungoides: final results from the EORTC cutaneous lymphoma task force phase III randomized clinical trial (NCT00056056). Br J Dermatol 2012; 167: 678-687.
73. Ramsay DL, Lish KM, Yalowitz CB, Soter NA: Ultraviolet- B phototherapy for early-stage cutaneous T-cell lymphoma. Arch Dermatol 1992; 128: 931-933.
74. Kim YH, Martinez G, Varghese A, Hoppe RT: Topical nitrogen mustard in the management of mycosis fungoides: update of the Stanford experience. Arch Dermatol 2003; 139: 165-173.
75. Duvic M, Martin AG, Kim Y, Olsen E, Wood GS, Crowley CA, Yocum RC: Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. Arch Dermatol 2001; 137: 581-593.
76. Whittaker SJ, Demierre MF, Kim EJ, Rook AH, Lerner A, Duvic M, Scarisbrick J, Reddy S, Robak T, Becker JC, Samtsov A, McCulloch W, Kim YH: Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. J Clin Oncol 2010; 28: 4485-4491.
77. Olsen EA, Kim YH, Kuzel TM, Pacheco TR, Foss FM, Parker S, Frankel SR, Chen C, Ricker JL, Arduino JM, Duvic M: Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol 2007; 25: 3109-3115.
78. De Masson A, Guitera P, Brice P, Moulonguet I, Mouly F, Bouaziz J-D, Battistella M, Madelaine I, Roux J, Ram-Wolff C, Cayuela J-M, Bachelez H, Bensussan A, Michel L, Bagot M: Long-term efficacy and safety of alemtuzumab in advanced primary cutaneous T-cell lymphomas. Br J Dermatol 2014; 170: 720-724.
79. Zinzani PL, Musuraca G, Tani M, Stefoni V, Marchi E, Fina M, Pellegrini C, Alinari L, Derenzini E, de Vivo A, Sabattini E, Pileri S, Baccarani M: Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma. J Clin Oncol 2007; 25: 4293-4297.